[1] Tsukita S, Oishi K, Akiyama T, et al. Specific proto-oncogenic tyrosine kinases of src family are enriched in cell-to-cell adherens junctions where the level of tyrosine phosphorylation is elevated[J]. J Cell Biol, 1991, 113(4): 867-879. DOI:10.1083/jcb.113.4.867. [2] Khan A, Taiyab A, Hasan G M, et al. Structural and functional insights into lyn kinase: from immune regulation to therapeutic targeting[J]. J Cell Biochem, 2026, 127: e70082. DOI:10.1002/jcb.70082. [3] Sen B, Johnson F M. Regulation of src family kinases in human cancers[J]. J Signal Transduct, 2011, 2011: 865819. DOI:10.1155/2011/865819. [4] Shirasawa M, Nakajima R, Zhou Y X, et al. Transcriptional activation mechanisms and target genes of the oncogene product tax of human T-cell leukemia virus type 1[J]. Genes, 2025, 16(10): 1221. DOI:10.3390/genes16101221. [5] Katayama M, Caria E, Van Simaeys D, et al. Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle[J]. J Sport Health Sci, 2026, 15: 101091. DOI:10.1016/j.jshs.2025.101091. [6] Islam R, Choudhary H H, Zhang F, et al. Microglial TLR4-Lyn kinase is a critical regulator of neuroinflammation, Aβ phagocytosis, neuronal damage, and cell survival in Alzheimer’s disease[J]. Sci Rep, 2025, 15: 11368. DOI:10.1038/s41598-025-96456-y. [7] Chen J L, Chu P Y, Huang C T, et al. Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma[J]. Clin Exp Med, 2025, 25: 345. DOI:10.1007/s10238-025-01874-x. [8] Dhakal H, Yang E J, Lee S, et al. Avenanthramide C from germinated oats exhibits anti-allergic inflammatory effects in mast cells[J]. Sci Rep, 2019, 9: 6884. DOI:10.1038/s41598-019-43412-2. [9] Ochi H, Watanabe T. Negative regulation of B cell receptor-mediated signaling in B-1 cells through CD5 and Ly49 co-receptors via Lyn kinase activity[J]. Int Immunol, 2000, 12(10): 1417-1423. DOI:10.1093/intimm/12.10.1417. [10] Iida M, Brand T M, Campbell D A, et al. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor[J]. Oncogene, 2019, 38(13): 2435. DOI:10.1038/s41388-018-0572-x. [11] Sinnett-Smith J, Anwar T, Reed E F, et al. Opposite effects of src family kinases on YAP and ERK activation in pancreatic cancer cells: implications for targeted therapy[J]. Mol Cancer Ther, 2022, 21(11): 1652-1662. DOI:10.1158/1535-7163.mct-21-0964. [12] Kapoor A, Yao W T, Ying H Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer[J]. Cell, 2019, 179(5): 1239. DOI:10.1016/j.cell.2019.10.037. [13] Kashiwakura J I, Kawahara S, Inagaki I, et al. STAP-2 negatively regulates BCR-mediated B cell activation by recruiting tyrosine-protein kinase CSK to LYN[J]. FEBS Lett, 2023, 597(19): 2433-2445. DOI:10.1002/1873-3468.14730. [14] Lin J S, Lai E M. Protein-protein interactions: yeast two hybrid[M] //Journet L, Cascales E. Bacterial Secretion Systems: Methods and Protocols. New York, NY: Springer US, 2024: 235-246. DOI:10.1007/978-1-0716-3445-5_15. [15] Shivhare D, Musialak-Lange M, Julca I, et al. Removing auto-activators from yeast-two-hybrid assays by conditional negative selection[J]. Sci Rep, 2021, 11: 5477. DOI:10.1038/s41598-021-84608-9. [16] Brodie E J, Infantino S, Low M S Y, et al. Lyn, lupus, and(B)lymphocytes, a lesson on the critical balance of kinase signaling in immunity[J]. Front Immunol, 2018, 9: 401. DOI:10.3389/fimmu.2018.00401. [17] Chan V W F, Lowell C A, DeFranco A L. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes[J]. Curr Biol, 1998, 8(10): 545-553. DOI:10.1016/S0960-9822(98)70223-4. [18] Alca^ntara A, Bosch J, Nazari F, et al. Systematic Y2H screening reveals extensive effector-complex formation[J]. Front Plant Sci, 2019, 10: 1437. DOI:10.3389/fpls.2019.01437. [19] Heintz V J, Wang L, LaCount D J. NanoLuc luciferase as a quantitative yeast two-hybrid reporter[J]. FEMS Yeast Res, 2022, 21(8): foab069. DOI:10.1093/femsyr/foab069. [20] Xiang Z, Huang X, Wang J X, et al. Cross-database analysis reveals sensitive biomarkers for combined therapy for ERBB2+ gastric cancer[J]. Front Pharmacol, 2018, 9: 861. DOI:10.3389/fphar.2018.00861. [21] Xiong D, Tong C S, Wu M. A molecular systems perspective on calcium oscillations beyond ion fluxes[J]. Curr Opin Cell Biol, 2025, 94: 102523. DOI:10.1016/j.ceb.2025.102523. [22] Odom S, Gomez G, Kovarova M, et al. Negative regulation of immunoglobulin E-dependent allergic responses by lyn kinase[J]. J Exp Med, 2004, 199(11): 1491-1502. DOI:10.1084/jem.20040382. [23] Wang X Y, Li Y, Luo D Y, et al. Lyn regulates mucus secretion and MUC5AC via the STAT6 signaling pathway during allergic airway inflammation[J]. Sci Rep, 2017, 7: 42675. DOI:10.1038/srep42675. [24] Zhu Y M, Bertics P J. Chemoattractant-induced signaling via the ras-ERK and PI3K-Akt networks, along with leukotriene C4 release, is dependent on the tyrosine kinase lyn in IL-5- and IL-3-primed human blood eosinophils[J]. J Immunol, 2011, 186(1): 516-526. DOI:10.4049/jimmunol.1000955. [25] Smith P G, Tanaka H, Chantry A. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells[J]. Oncotarget, 2012, 3(5): 518-524. DOI:10.18632/oncotarget.500. [26] Li G P, Fox J III, Liu J, et al. Lyn mitigates mouse airway remodeling by downregulating the TGF-β3 isoform in house dust mite models[J]. J Immunol, 2013, 191(11): 5359-5370. DOI:10.4049/jimmunol.1301596. [27] Lefaudeux D, De Meulder B, Loza M J, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics[J]. J Allergy Clin Immunol, 2017, 139(6): 1797-1807. DOI:10.1016/j.jaci.2016.08.048. [28] De Fátima Ferreira Borges Da Costa J, De Castro SANT' Anna C, Muniz J A P C, et al. Deregulation of the SRC family tyrosine kinases in gastric carcinogenesis in non-human Primates[J]. Anticancer Res, 2018, 38(11): 6317-6320. DOI:10.21873/anticanres.12988. [29] Kumar A, Jaggi A S, Singh N. Pharmacology of Src family kinases and therapeutic implications of their modulators[J]. Fundamemntal Clinical Pharma, 2015, 29(2): 115-130. DOI:10.1111/fcp.12097. [30] Tabariès S, Annis M G, Hsu B E, et al. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis[J]. Oncotarget, 2015, 6(11): 9476-9487. DOI:10.18632/oncotarget.3269. [31] Ergün S, Akgün O, Hekim N T, et al. The interrelationship between FYN and miR-128/193a-5p/494 in imatinib resistancein prostate cancer[J]. Anti Cancer Agents Med Chem, 2023, 23(3): 360-365. DOI:10.2174/1871520622666220601093452. [32] L’Estrange-Stranieri E, Gottschalk T A, Wright M D, et al. The dualistic role of Lyn tyrosine kinase in immune cell signaling: implications for systemic lupus erythematosus[J]. Front Immunol, 2024, 15: 1395427. DOI:10.3389/fimmu.2024.1395427. ( |